CCP
VIR icon

Clough Capital Partners’s Vir Biotechnology VIR Stock Holding History

Clough Capital Partners’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-199,563
Closed -$6.85M – 152
2020
Q3 		$6.85M Buy
+199,563
New +$8.59M 0.49% 62

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
APF
Alaska Permanent Fund Juneau, Alaska $1.51B AUM 22.23% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

Clough Capital Partners's VIR Position: Q4 2020 in Review

Clough Capital Partners sold out of Vir Biotechnology (VIR) in Q4 2020, closing a stake of 199,563 shares — an estimated $6.85M sold.

Clough Capital Partners first reported a position in VIR in Q3 2020 and held it in 1 quarter. The position peaked at $6.85M in Q3 2020. 143 funds tracked by Wall St. Rank hold VIR as of Q4 2020.

  • Clough Capital Partners reported no remaining Vir Biotechnology position as of Q4 2020 after selling out during the quarter.
  • Clough Capital Partners sold 199,563 Vir Biotechnology shares in Q4 2020, an estimated $6.85M.
  • Clough Capital Partners first reported a position in Vir Biotechnology in Q3 2020 and held it in 1 quarter.
  • Clough Capital Partners's Vir Biotechnology position peaked at $6.85M in Q3 2020.
  • 143 funds tracked by Wall St. Rank held Vir Biotechnology as of Q4 2020.

Based on Clough Capital Partners's 13F filing for Q4 2020, filed 16 Feb 2021.